Genmab A-S

Yahoo Finance • yesterday

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In.In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich undervalued stocks. Currently, big tech and... Full story

Yahoo Finance • 5 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the t... Full story

Yahoo Finance • 9 days ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Co... Full story

Yahoo Finance • 12 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preempti... Full story

Yahoo Finance • 17 days ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Media Release COPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma... Full story

Yahoo Finance • 18 days ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S(Nasdaq:GMAB)announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45t... Full story

Yahoo Finance • 24 days ago

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET... Full story

Yahoo Finance • 25 days ago

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Total Revenue Growth: 31% increase in 2024. Operating Profit Growth: 26% increase in 2024. Cash Position: Nearly $3 billion at year-end 2024. Acquisition: $1.8 billion acquisition of ProfoundBio. Share Buyback: $500 million in 2024. EPKINL... Full story

Yahoo Finance • 25 days ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on For... Full story

Yahoo Finance • 25 days ago

Genmab Publishes 2024 Annual Report

Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and... Full story

Yahoo Finance • last month

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiar... Full story

Yahoo Finance • 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genma... Full story

Yahoo Finance • 5 months ago

Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics

We recently published a list of 12 Most Profitable Growth Stocks To Invest In. In this article, we are going to take a look at where Genmab (NASDAQ:GMAB) stands against other most profitable growth stocks to invest in. After the September... Full story

Yahoo Finance • 5 months ago

Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other best revenue growth stocks to buy accord... Full story

Yahoo Finance • 6 months ago

Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers

We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers.In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other affordable stocks under $40. Several... Full story

Yahoo Finance • 7 months ago

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products Monday, BioNTech SE (NASDAQ:BNTX) reported deeper losses in the second quarter of 2024, with an EPS loss of... Full story

Yahoo Finance • 8 months ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Genmab A/S Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcorita... Full story

Yahoo Finance • 9 months ago

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Genmab A/S Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with r... Full story

Yahoo Finance • 10 months ago

Genmab Completes Acquisition of ProfoundBio

Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-d... Full story

Yahoo Finance • 10 months ago

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive... Full story